Search Results

There are 13416 results for: content related to: Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study

  1. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study

    British Journal of Dermatology

    Volume 167, Issue 3, September 2012, Pages: 658–667, C. Leonardi, J.M. Sobell, J.J. Crowley, U. Mrowietz, Y. Bao, P.M. Mulani, Y. Gu and M.M. Okun

    Version of Record online : 20 AUG 2012, DOI: 10.1111/j.1365-2133.2012.11041.x

  2. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients

    Journal of the European Academy of Dermatology and Venereology

    Volume 27, Issue 5, May 2013, Pages: 593–600, P.P.M. van Lümig, P.C.M. van de Kerkhof, J.B.M. Boezeman, R.J.B. Driessen and E.M.G.J. de Jong

    Version of Record online : 15 MAR 2012, DOI: 10.1111/j.1468-3083.2012.04496.x

  3. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept

    British Journal of Dermatology

    Volume 163, Issue 4, October 2010, Pages: 838–846, P.P.M. Van Lümig, L.L.A. Lecluse, R.J.B. Driessen, P.I. Spuls, J.B. Boezeman, P.C.M. Van De Kerkhof and E.M.G.J. De Jong

    Version of Record online : 22 JUL 2010, DOI: 10.1111/j.1365-2133.2010.09950.x

  4. You have free access to this content
    Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

    The Journal of Dermatology

    Volume 37, Issue 4, April 2010, Pages: 299–310, Akihiko ASAHINA, Hidemi NAKAGAWA, Takafumi ETOH, Mamitaro OHTSUKI and THE ADALIMUMAB M04-688 STUDY GROUP

    Version of Record online : 26 FEB 2010, DOI: 10.1111/j.1346-8138.2009.00748.x

  5. Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis

    Journal of the European Academy of Dermatology and Venereology

    N.M. Mostafa, A.M. Nader, P. Noertersheuser, M. Okun and W.M. Awni

    Version of Record online : 22 AUG 2016, DOI: 10.1111/jdv.13884

  6. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis

    British Journal of Dermatology

    Volume 167, Issue s3, November 2012, Pages: 12–20, J. Leman and A.D. Burden

    Version of Record online : 22 OCT 2012, DOI: 10.1111/j.1365-2133.2012.11209.x

  7. S3 – Guidelines on the treatment of psoriasis vulgaris (English version). Update

    JDDG: Journal der Deutschen Dermatologischen Gesellschaft

    Volume 10, Issue s2, March 2012, Pages: S1–s95, Alexander Nast, Wolf-Henning Boehncke, Ulrich Mrowietz, Hans-Michael Ockenfels, Sandra Philipp, Kristian Reich, Thomas Rosenbach, Adel Sammain, Martin Schlaeger, Michael Sebastian, Wolfram Sterry, Volker Streit, Matthias Augustin, Ricardo Erdmann, Joachim Klaus, Joachim Koza, Siegrid Muller, Hans-Dieter Orzechowski, Stefanie Rosumeck, Gerhard Schmid-Ott, Tobias Weberschock and Berthold Rzany

    Version of Record online : 5 MAR 2012, DOI: 10.1111/j.1610-0387.2012.07919.x

  8. You have free access to this content
    Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: Results in a single community-based hospital

    The Journal of Dermatology

    Volume 39, Issue 3, March 2012, Pages: 265–268, Shinji NODA, Kyoko MIZUNO and Makoto ADACHI

    Version of Record online : 29 NOV 2011, DOI: 10.1111/j.1346-8138.2011.01312.x

  9. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE

    Journal of the European Academy of Dermatology and Venereology

    Volume 25, Issue 9, September 2011, Pages: 1012–1020, J.-P. Ortonne, S. Chimenti, K. Reich, R. Gniadecki, P. Sprøgel, K. Unnebrink, H. Kupper, O. Goldblum and D. Thaçi

    Version of Record online : 9 JAN 2011, DOI: 10.1111/j.1468-3083.2010.03944.x

  10. Efficacy of biologics in the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials with different time points

    Journal of the European Academy of Dermatology and Venereology

    Volume 28, Issue 12, December 2014, Pages: 1633–1653, L. Puig, A. López, E. Vilarrasa and I. García

    Version of Record online : 19 AUG 2013, DOI: 10.1111/jdv.12238

  11. You have free access to this content
    European S3-Guidelines on the systemic treatment of psoriasis vulgaris

    Journal of the European Academy of Dermatology and Venereology

    Volume 23, Issue s2, October 2009, Pages: 1–70, D Pathirana, AD Ormerod, P Saiag, C Smith, PI Spuls, A Nast, J Barker, JD Bos, G-R Burmester, S Chimenti, L Dubertret, B Eberlein, R Erdmann, J Ferguson, G Girolomoni, P Gisondi, A Giunta, C Griffiths, H Hönigsmann, M Hussain, R Jobling, S-L Karvonen, L Kemeny, I Kopp, C Leonardi, M Maccarone, A Menter, U Mrowietz, L Naldi, T Nijsten, J-P Ortonne, H-D Orzechowski, T Rantanen, K Reich, N Reytan, H Richards, HB Thio, P Van De Kerkhof and B Rzany

    Version of Record online : 26 AUG 2009, DOI: 10.1111/j.1468-3083.2009.03389.x

    Corrected by:

    Erratum

    Vol. 24, Issue 1, 117–118, Version of Record online: 7 DEC 2009

  12. You have full text access to this OnlineOpen article
    Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption

    Journal of the European Academy of Dermatology and Venereology

    Volume 29, Issue 4, April 2015, Pages: 767–776, K.B. Gordon, A.B. Gottlieb, R.G. Langely, P. van de Kerkhof, K.T. Belasco, M. Sundaram, M. Okun and L. Serra

    Version of Record online : 3 OCT 2014, DOI: 10.1111/jdv.12677

  13. An observational, prospective study of monthly adalimumab therapy for disease maintenance in psoriasis patients: a possible new therapeutic option for good responders to the initial induction treatment

    Journal of the European Academy of Dermatology and Venereology

    Volume 27, Issue 11, November 2013, Pages: 1444–1447, T. Taniguchi, S. Noda, N. Takahashi, H. Yoshimura, K. Mizuno and M. Adachi

    Version of Record online : 15 JUN 2012, DOI: 10.1111/j.1468-3083.2012.04610.x

  14. Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment

    Journal of the European Academy of Dermatology and Venereology

    Volume 26, Issue 11, November 2012, Pages: 1331–1344, T.C. Lucka, D. Pathirana, A. Sammain, F. Bachmann, S. Rosumeck, R. Erdmann, J. Schmitt, H. Orawa, B. Rzany and A. Nast

    Version of Record online : 9 MAR 2012, DOI: 10.1111/j.1468-3083.2012.04492.x

  15. You have free access to this content
    Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial

    Arthritis & Rheumatism

    Volume 56, Issue 2, February 2007, Pages: 476–488, Dafna D. Gladman, Philip J. Mease, Christopher T. Ritchlin, Ernest H. S. Choy, John T. Sharp, Peter A. Ory, Renee J. Perdok and Eric H. Sasso

    Version of Record online : 30 JAN 2007, DOI: 10.1002/art.22379

  16. Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis

    British Journal of Dermatology

    Volume 171, Issue 4, October 2014, Pages: 875–883, S.P. Menting, A.S. Sitaram, H.M. Bonnerjee-van der Stok, M.A. de Rie, L. Hooft and Ph.I. Spuls

    Version of Record online : 20 AUG 2014, DOI: 10.1111/bjd.13001

  17. Anti-TNF agents for paediatric psoriasis

    Intervention Review

    The Cochrane Library

    Gloria Sanclemente, Ruth Murphy, Javier Contreras, Hermenegildo García and Xavier Bonfill Cosp

    Published Online : 24 NOV 2015, DOI: 10.1002/14651858.CD010017.pub2

  18. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)

    British Journal of Dermatology

    Volume 158, Issue 3, March 2008, Pages: 558–566, J.-H. Saurat, G. Stingl, L. Dubertret, K. Papp, R.G. Langley, J.-P. Ortonne, K. Unnebrink, M. Kaul, A. Camez and for the CHAMPION Study Investigators

    Version of Record online : 28 NOV 2007, DOI: 10.1111/j.1365-2133.2007.08315.x

  19. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study

    Journal of the European Academy of Dermatology and Venereology

    Volume 29, Issue 2, February 2015, Pages: 353–360, D. Thaçi, K. Unnebrink, M. Sundaram, S. Sood and Y. Yamaguchi

    Version of Record online : 21 MAY 2014, DOI: 10.1111/jdv.12553

  20. Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response

    British Journal of Dermatology

    Volume 172, Issue 2, February 2015, Pages: 504–512, J.E. Signorovitch, K.A. Betts, Y.S. Yan, C. LeReun, M. Sundaram, E.Q. Wu and P. Mulani

    Version of Record online : 21 JAN 2015, DOI: 10.1111/bjd.13437